332 related articles for article (PubMed ID: 22241679)
1. Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS).
Sussman DA; Kubiliun N; Mulani PM; Chao J; Gillis CA; Yang M; Lu M; T Abreu M
Inflamm Bowel Dis; 2012 Nov; 18(11):2043-55. PubMed ID: 22241679
[TBL] [Abstract][Full Text] [Related]
2. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
[TBL] [Abstract][Full Text] [Related]
3. Elective switching from infliximab to adalimumab in stable Crohn's disease.
Hoentjen F; Haarhuis BJ; Drenth JP; de Jong DJ
Inflamm Bowel Dis; 2013; 19(4):761-6. PubMed ID: 23446337
[TBL] [Abstract][Full Text] [Related]
4. A retrospective comparison of infliximab versus adalimumab as induction and maintenance therapy for Crohn disease.
Varma P; Paul E; Huang C; Headon B; Sparrow MP
Intern Med J; 2016 Jul; 46(7):798-804. PubMed ID: 26865349
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents.
Kestens C; van Oijen MG; Mulder CL; van Bodegraven AA; Dijkstra G; de Jong D; Ponsioen C; van Tuyl BA; Siersema PD; Fidder HH; Oldenburg B;
Clin Gastroenterol Hepatol; 2013 Jul; 11(7):826-31. PubMed ID: 23376000
[TBL] [Abstract][Full Text] [Related]
6. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
[TBL] [Abstract][Full Text] [Related]
7. A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn's Disease Treated with Adalimumab or Infliximab.
Yokoyama K; Yamazaki K; Katafuchi M; Ferchichi S
Adv Ther; 2016 Nov; 33(11):1947-1963. PubMed ID: 27664107
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease.
Narula N; Kainz S; Petritsch W; Haas T; Feichtenschlager T; Novacek G; Eser A; Vogelsang H; Reinisch W; Papay P
Aliment Pharmacol Ther; 2016 Jul; 44(2):170-80. PubMed ID: 27226407
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
[TBL] [Abstract][Full Text] [Related]
10. Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience.
Olivera P; Thiriet L; Luc A; Baumann C; Danese S; Peyrin-Biroulet L
Inflamm Bowel Dis; 2017 Jun; 23(6):976-985. PubMed ID: 28333755
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres.
Tursi A; Elisei W; Picchio M; Penna A; Lecca PG; Forti G; Giorgetti G; Faggiani R; Zampaletta C; Pelecca G; Brandimarte G
Eur J Intern Med; 2014 Jun; 25(5):485-90. PubMed ID: 24631020
[TBL] [Abstract][Full Text] [Related]
12. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
Gisbert JP; Marín AC; McNicholl AG; Chaparro M
Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of anti-TNF agents for Crohn's disease in a tertiary referral IBD practice.
Patil SA; Rustgi A; Langenberg P; Cross RK
Dig Dis Sci; 2013 Jan; 58(1):209-15. PubMed ID: 23014844
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis.
Ananthakrishnan AN; Cagan A; Cai T; Gainer VS; Shaw SY; Savova G; Churchill S; Karlson EW; Kohane I; Liao KP; Murphy SN
Inflamm Bowel Dis; 2016 Apr; 22(4):880-5. PubMed ID: 26933751
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.
Cosnes J; Sokol H; Bourrier A; Nion-Larmurier I; Wisniewski A; Landman C; Marteau P; Beaugerie L; Perez K; Seksik P
Aliment Pharmacol Ther; 2016 Nov; 44(10):1102-1113. PubMed ID: 27666569
[TBL] [Abstract][Full Text] [Related]
16. Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocaecal resection for crohn's disease: results from the MULTIPER database.
Kotze PG; Yamamoto T; Danese S; Suzuki Y; Teixeira FV; de Albuquerque IC; Saad-Hossne R; de Barcelos IF; da Silva RN; da Silva Kotze LM; Olandoski M; Sacchi M; Yamada A; Takeuchi K; Spinelli A
J Crohns Colitis; 2015 Jul; 9(7):541-7. PubMed ID: 25820017
[TBL] [Abstract][Full Text] [Related]
17. Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease.
Choi GK; Collins SD; Greer DP; Warren L; Dowson G; Clark T; Hamlin PJ; Ford AC
J Crohns Colitis; 2014 May; 8(5):375-83. PubMed ID: 24129316
[TBL] [Abstract][Full Text] [Related]
18. Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center.
Nobile S; Gionchetti P; Rizzello F; Calabrese C; Campieri M
Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):458-65. PubMed ID: 24445727
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effectiveness of infliximab and adalimumab in preventing postoperative recurrence in patients with Crohn's disease: an open-label, pilot study.
Tursi A; Elisei W; Picchio M; Zampaletta C; Pelecca G; Faggiani R; Brandimarte G
Tech Coloproctol; 2014 Nov; 18(11):1041-6. PubMed ID: 24915941
[TBL] [Abstract][Full Text] [Related]
20. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]